EOX方案联合派姆单抗治疗微卫星不稳定型晚期胃癌患者的效果评价  

Efficacy evaluation of EOX regimen combined with Pembrolizumab on patients with microsatellite unstable advanced gastric cancer

作　　者：孙东方 赵建辉 SUN Dong-fang;ZHAO Jian-hui(General Surgery,Yan'an University Xianyang Hospital,Xianyang,Shaanxi 712000,China)

机构地区：[1]延安大学咸阳医院普通外科,陕西咸阳712000

出　　处：《中国卫生检验杂志》2022年第20期2488-2492,共5页Chinese Journal of Health Laboratory Technology

基　　金：陕西省社会发展科技攻关项目(2016SF-107)。

摘　　要：目的探讨表阿霉素、奥沙利铂联合卡培他滨(EOX)方案联合派姆单抗治疗微卫星不稳定型晚期胃癌患者的效果及对糖链抗原72-4(CA72-4)、糖链抗原19-9(CA19-9)、癌胚抗原(CEA)的影响。方法选择2019年1月—2021年6月本院收治的116例微卫星不稳定型晚期胃癌患者,采用随机数字表法分为观察组与对照组各58例。对照组予EOX方案治疗,观察组在对照组EOX方案基础上联合派姆单抗治疗。比较2组近期疗效、毒副反应、血清CA72-4、CA19-9、CEA水平、免疫细胞CD3^(+)、CD4^(+)、CD8^(+)水平及生存期。结果观察组治疗有效率高于对照组,比较差异有统计学意义(χ^(2)=8.048,P<0.05);观察组生活质量改善率高于对照组(χ^(2)=2.505,P<0.05);观察组治疗后血清CA72-4、CA19-9、CEA水平低于对照组(P<0.05);2组非血液学及血液学不良反应发生率比较差异均无统计学意义(P>0.05);治疗后观察组患者血免疫细胞CD3^(+)、CD4^(+)、CD8^(+)水平高于对照组;2组患者生存期差异无统计学意义。结论EOX方案联合派姆单抗治疗微卫星不稳定型晚期胃癌患可提高治疗疗效,改善患者生活质量。Objective To investigate the efficacy of Epiaminomycin,oxaliplatin in combination with capecitabine(EOX)regimen combined with Pembrolizumab in the treatment of microsatellite unstable advanced gastric cancer and its effect on CA72-4,CA19-9 and carcinoma embryonic antigen(CEA).Methods A total of 116 patients with amicrosatellite unstable advanced gastric cancer treated in our hospital from January 2019 to June 2021 were randomly divided into observation group and control group.The control group was treated with EOX regimen,and the observation group was treated with Pemzumab on the basis of EOX regimen.The short-term efficacy,toxic and side effects,serum CA72-4,CA19-9 and CEA levels,the level of blood immune cells(CD3,CD4,CD8)and overall survival rate were compared between the two groups.Results The effective rate of the observation group was higher than that of the control group,with the differences statistically significant(χ^(2)=8.048,P<0.05);the improvement rate of quality of life in the observation group was higher than that in the control group(χ^(2)=2.505,P<0.05);the levels of CA72-4,CA19-9 and CEA in the observation group were lower than those in the control group(P<0.05);there was no statistical significance on the difference in the incidence of non-hematological and hematological adverse reactions between the two groups(P>0.05);after treatment,the level of blood immune cells(CD3,CD4,CD8)in the observation group was higher than that in the control group;there was no statistical significance on the difference in survival time between the two groups(P>0.05).Conclusion EOX regimen combined with Pembrolizumab in the treatment of microsatellite unstable advanced gastric cancer can improve the therapeutic effect and improve the quality of life of patients.

关 键 词：晚期胃癌 EOX 糖链抗原72-4 糖链抗原19-9 癌胚抗原 生存 

分 类 号：R730.4[医药卫生—肿瘤]